N-acetylcysteine has a genuinely different origin story than most entries in this Atlas — it's not a traditional remedy at all, but a modified amino acid developed through 20th-century pharmaceutical chemistry. Its most well-established, uncontested medical use is as the standard emergency antidote for acetaminophen overdose, used in hospitals worldwide.
NAC's supplement-market popularity centers on its role as a precursor to glutathione, and its traditional pharmaceutical use as a mucus-thinning agent — an application whose more recent evidence has become a genuinely instructive case of directly conflicting meta-analyses.
NAC's evidence for COPD — its most-studied wellness-relevant application — presents a genuine, unresolved disagreement. One meta-analysis, including 9 randomized controlled trials (over 2,000 patients), found oral NAC did not significantly reduce exacerbation risk or improve lung function decline. A separate, independently-conducted meta-analysis of 12 trials (2,691 patients) reached the opposite conclusion, finding both high-dose and low-dose NAC significantly reduced COPD exacerbation prevalence.
This is a genuine scientific disagreement rather than simple inconsistency — different meta-analyses, examining overlapping but not identical trials, reaching opposite conclusions on the same outcome in the same patient population. Given this real, unresolved tension between reasonably substantial independent meta-analyses, "Limited-Moderate" is the honest, transparent rating.
Not applicable — a synthesized pharmaceutical/supplement compound, not a traditional herbal preparation.